Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
24
pubmed:dateCreated
2002-6-10
pubmed:abstractText
The human dopamine transporter (hDAT) contains an endogenous high affinity Zn2+ binding site with three coordinating residues on its extracellular face (His193, His375, and Glu396). Upon binding to this site, Zn2+ causes inhibition of [3H]1-methyl-4-phenylpyridinium ([3H]MPP+) uptake. We investigated the effect of Zn2+ on outward transport by superfusing hDAT-expressing HEK-293 cells preloaded with [3H]MPP+. Although Zn2+ inhibited uptake, Zn2+ facilitated [3H]MPP+ release induced by amphetamine, MPP+, or K+-induced depolarization specifically at hDAT but not at the human serotonin and the norepinephrine transporter (hNET). Mutation of the Zn2+ coordinating residue His(193) to Lys (the corresponding residue in hNET) eliminated the effect of Zn2+ on efflux. Conversely, the reciprocal mutation (K189H) conferred Zn2+ sensitivity to hNET. The intracellular [3H]MPP+ concentration was varied to generate saturation isotherms; these showed that Zn2+ increased V(max) for efflux (rather than K(M-Efflux-intracellular)). Thus, blockage of inward transport by Zn2+ is not due to a simple inhibition of the transporter turnover rate. The observations provide evidence against the model of facilitated exchange-diffusion and support the concept that inward and outward transport represent discrete operational modes of the transporter. In addition, they indicate a physiological role of Zn2+, because Zn2+ also facilitated transport reversal of DAT in rat striatal slices.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0021-9258
pubmed:author
pubmed:issnType
Print
pubmed:day
14
pubmed:volume
277
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
21505-13
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:11940571-Amphetamines, pubmed-meshheading:11940571-Animals, pubmed-meshheading:11940571-Binding Sites, pubmed-meshheading:11940571-Biological Transport, pubmed-meshheading:11940571-Cell Line, pubmed-meshheading:11940571-DNA, Complementary, pubmed-meshheading:11940571-Dopamine, pubmed-meshheading:11940571-Dose-Response Relationship, Drug, pubmed-meshheading:11940571-Female, pubmed-meshheading:11940571-Humans, pubmed-meshheading:11940571-Ions, pubmed-meshheading:11940571-Kinetics, pubmed-meshheading:11940571-Membrane Glycoproteins, pubmed-meshheading:11940571-Membrane Transport Proteins, pubmed-meshheading:11940571-Mutation, pubmed-meshheading:11940571-Neuropeptides, pubmed-meshheading:11940571-Norepinephrine, pubmed-meshheading:11940571-Potassium, pubmed-meshheading:11940571-Rats, pubmed-meshheading:11940571-Rats, Sprague-Dawley, pubmed-meshheading:11940571-Temperature, pubmed-meshheading:11940571-Time Factors, pubmed-meshheading:11940571-Transfection, pubmed-meshheading:11940571-Vesicular Biogenic Amine Transport Proteins, pubmed-meshheading:11940571-Zinc
pubmed:year
2002
pubmed:articleTitle
The role of zinc ions in reverse transport mediated by monoamine transporters.
pubmed:affiliation
Institute of Pharmacology, University of Vienna, Währingerstrasse 13a, A-1090 Vienna, Austria.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't